Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezuclastinib in Nonadvanced Systemic Mastocytosis
NCT05186753Phase 2Active, not recruiting
- Sponsor
- Cogent Biosciences
- Start
- Jun 2022
- Primary completion
- May 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
A Phase 2 trial of bezuclastinib in systemic mastocytosis (SM), sponsored by Cogent Biosciences. Started Jun 2022; status: active, not recruiting.
02
Drugs
bezuclastinib
03
Conditions
systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT05186753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05186753.